In vitro and in vivo approaches to tumor targeting by phage display
Metadata[+] Show full item record
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Approximately 30% of breast cancers are linked with the over-expression of ErbB2. Because of its critical role in signal transduction, the progression of breast cancer and its localization on the surface of several types of cancer cells, ErbB2 is a commonly used as a target for the search for protein and peptide ligands that may be useful as therapeutic and diagnostic agents for treating and imaging cancer. In the work described here, I used several commonly used in vitro, ex vivo, and in vivo phage display techniques and binding assays in an attempt to discover such peptides. This work lead to the discovery a phage mutant which interferes with the usage of the phage display libraries of the type used during this research. In addition, I also report the results of a quantitative assessment of a new enzymatically releasable phage construct.
Access is limited to the campuses of the University of Missouri.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.